These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15885349)

  • 1. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
    Schaefer M; Schwaiger M; Garkisch AS; Pich M; Hinzpeter A; Uebelhack R; Heinz A; van Boemmel F; Berg T
    J Hepatol; 2005 Jun; 42(6):793-8. PubMed ID: 15885349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
    Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
    Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
    Morasco BJ; Rifai MA; Loftis JM; Indest DW; Moles JK; Hauser P
    J Affect Disord; 2007 Nov; 103(1-3):83-90. PubMed ID: 17292481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
    Kraus MR; Schäfer A; Schöttker K; Keicher C; Weissbrich B; Hofbauer I; Scheurlen M
    Gut; 2008 Apr; 57(4):531-6. PubMed ID: 18079286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S; Avasthi A; Grover S; Chawla YK
    J Psychosom Res; 2014 Aug; 77(2):109-15. PubMed ID: 25077851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial.
    Klein MB; Lee T; Brouillette MJ; Sheehan NL; Walmsley S; Wong DK; Conway B; Hull M; Cooper C; Haidar S; Vezina S; Annable L; Young S; Zubyk W; Singer J
    HIV Clin Trials; 2014; 15(4):161-75. PubMed ID: 25143025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
    Diez-Quevedo C; Masnou H; Planas R; Castellví P; Giménez D; Morillas RM; Martín-Santos R; Navinés R; Solà R; Giner P; Ardèvol M; Costa J; Diago M; Pretel J
    J Clin Psychiatry; 2011 Apr; 72(4):522-8. PubMed ID: 21034680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.
    Quarantini LC; Bressan RA; Galvão A; Batista-Neves S; Paraná R; Miranda-Scippa A
    Liver Int; 2007 Oct; 27(8):1098-102. PubMed ID: 17845538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
    Schaefer M; Mauss S
    Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
    Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
    Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.
    Hauser P; Khosla J; Aurora H; Laurin J; Kling MA; Hill J; Gulati M; Thornton AJ; Schultz RL; Valentine AD; Meyers CA; Howell CD
    Mol Psychiatry; 2002; 7(9):942-7. PubMed ID: 12399946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial.
    Morasco BJ; Loftis JM; Indest DW; Ruimy S; Davison JW; Felker B; Hauser P
    Psychosomatics; 2010; 51(5):401-8. PubMed ID: 20833939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.
    Castera L; Constant A; Henry C; Champbenoit P; Bernard PH; De Ledinghen V; Demotes-Mainard J; Couzigou P
    Aliment Pharmacol Ther; 2006 Oct; 24(8):1223-30. PubMed ID: 17014581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders.
    Dell'Osso L; Pini S; Maggi L; Rucci P; Del Debbio A; Carlini M; Baldini A; Ferrari G; Manca E; Beverini E; Amore M; Scarallo V; Semeraro Q; Brunetto M; Bonino F; Maj M
    J Psychosom Res; 2007 Mar; 62(3):349-55. PubMed ID: 17324686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis.
    Udina M; Castellví P; Moreno-España J; Navinés R; Valdés M; Forns X; Langohr K; Solà R; Vieta E; Martín-Santos R
    J Clin Psychiatry; 2012 Aug; 73(8):1128-38. PubMed ID: 22967776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
    Raison CL; Broadwell SD; Borisov AS; Manatunga AK; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
    Brain Behav Immun; 2005 Jan; 19(1):23-7. PubMed ID: 15581735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals.
    Galvão-de Almeida A; Quarantini LC; Batista-Neves S; Lyra AC; Paraná R; de Oliveira IR; Miranda-Scippa A; Guindalini C
    World J Biol Psychiatry; 2010 Oct; 11(7):914-8. PubMed ID: 20642400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.
    Neri S; Pulvirenti D; Bertino G
    Clin Drug Investig; 2006; 26(11):655-62. PubMed ID: 17163300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.